Item 7.01 Regulation FD Disclosure.
On November 21, 2022, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) made
available an updated corporate strategy presentation (the “Presentation”) on the
Investor Relations section of the Company’s website. A copy of the Presentation
is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
The foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01
and will not be deemed to be filed for purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be
subject to the liabilities of that section, nor will it be deemed to be
incorporated by reference in any filing under the Securities Act of 1933, as
amended (the “Securities Act”), or the Exchange Act. The information contained
in the Presentation is summary information that should be considered in the
context of the Company’s filings with the Securities and Exchange Commission
(the “SEC”) and other public announcements the Company may make by press release
or otherwise from time to time.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made herein that are not historical facts are forward-looking
statements for purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Forward-looking statements generally
are accompanied by words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,”
“predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar
expressions that predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements include, but
are not limited to, statements regarding future events, including the
development and efficacy of our influenza program, C. diff. program, Type 1
Diabetes program, and other discovery programs, the likelihood that a patent
will issue from any patent application, the results, including timing, of the
development of SAB-176, SAB-185 and SAB-195 (including any IND filing or
proposed clinical trials), financial projections and future financial and
operating results (including estimated cost savings and cash runway), the
outcome of and potential future government and other third-party collaborations
or funded programs (including negotiations with the DoD).
These statements are based on the current expectations of SAB and are not
predictions of actual performance, and are not intended to serve as, and must
not be relied on, by any investor as a guarantee, prediction, definitive
statement, or an assurance, of fact or probability. These statements are only
current predictions or expectations, and are subject to known and unknown risks,
uncertainties and other factors which may be beyond our control. Actual events
and circumstances are difficult or impossible to predict, and these risks and
uncertainties may cause our or our industry’s results, performance, or
achievements to be materially different from those anticipated by these
forward-looking statements. A further description of risks and uncertainties can
be found in the sections captioned “Risk Factors” in our most recent annual
report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other
filings with or submissions to, the SEC, which are available at
https://www.sec.gov/. Except as otherwise required by law, SAB disclaims any
intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new
information, future events, or circumstances or otherwise.
Item 8.01 Other Events.
As previously disclosed, on October 5, 2022, the Company received a written
notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company
that it was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the
closing bid price for the Company’s common stock was below the $1.00 per share
requirement for the 30 consecutive business days preceding the written
On November 21, 2022, the Company received a written notification from Nasdaq
notifying the Company that Nasdaq has determined that for ten (10) consecutive
business days, from November 7, 2022 to November 18, 2022, the minimum closing
bid price for the Company’s common stock was at least $1.00 per share.
Accordingly, Nasdaq has determined that the Company has regained compliance with
Listing Rule 5450(a)(1) and it has indicated that the matter is now closed.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number Description 99.1 Presentation dated November 21, 2022 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
© Edgar Online, source Glimpses